With access to antiretroviral therapy (ART), human immunodeficiency virus (HIV)-infected men and women are living longer and healthier lives and have childbearing desires similar to those of HIV-uninfected individuals [1]. Many are in HIV-serodiscordant sexual partnerships (with an HIV-uninfected partner), and attempts at conception confer sexual HIV transmission risk [2]. HIV risk reduction strategies are available for HIV-serodiscordant couples, in which the male is infected, who want to conceive (Table 1), but there are limited data to inform which or how many concurrent methods a couple should adopt. ART for the HIV-infected male partner is recommended regardless of conception plans, to reduce HIV transmission risk to partners and improve the man’s own health [11, 12]. Because adherence to ART is imperfect and genital shedding of HIV may occur even in the presence of suppressed plasma viral load, couples may seek additional methods to reduce transmission risk. For an uninfected woman wishing to conceive with an infected male partner who is receiving ART, oral preexposure prophylaxis (PrEP) may be a valuable option, particularly if use of ART or ART adherence by the male partner is limited. Combining PrEP for the female partner (oral tenofovir/emtricitabine, or TDF/FTC) – with ART administration to the male partner for safer conception has been acceptable in observational studies [13–15]. Because PrEP trials were conducted without receipt of ART by the infected partner and ART trials were conducted without receipt of PrEP by the uninfected partner, there are no direct clinical data to estimate the benefit of using PrEP and ART together to decrease periconception HIV transmission risk, compared with either intervention alone.

In this issue of The Journal of Infectious Diseases, Hoffman et al use a thoughtfully designed simulation model to investigate the role of PrEP, ART, or both in male-infected, HIV-serodiscordant couples who are attempting to conceive. When clinical data are limited, simulation models can help to inform decision-making. If multiple studies provide partial information, a single model can integrate available data. When data are equivocal or missing, investigators make explicit assumptions about which values to use in a model and then vary these values in sensitivity analyses to identify the thresholds at which decisions would change; this allows readers to understand whether more data are needed to accurately inform clinical choices [16]. Here, Hoffman et al combine transmission risks from separate PrEP trials, ART-as-prevention trials, and observational studies of age-stratified pregnancy rates, and conduct extensive sensitivity analyses on key model parameters. They focus this analysis on couples who maintain the high rates of ART-mediated viral suppression and PrEP adherence seen in the HPTN 052 and Partners PrEP trials [3, 5, 17, 18]. They also assume that both partners are aware of each others’ HIV status, have been screened and treated for sexually transmitted infections (STIs), and have completed normal fertility evaluations. There are 3 primary messages from their analysis.

First, if couples limit condomless sex to the 2 days before and the day of ovulation, and if the male partner is receiving virally suppressive ART, PrEP for the female partner provides little additional benefit. The authors define a “successful” outcome as one in which the female partner remains uninfected and a full-term pregnancy occurs. With ART alone, the yearly chance of this successful outcome is 29.1%; with ART plus PrEP, this chance is 29.2%, which is essentially equivalent within the margin of error of the model results.

Second, if couples choose a single intervention, ART for the male partner is projected to be more effective in reducing transmission than PrEP for the female
partners. When neither ART nor PrEP are used, the yearly HIV transmission risk predicted by the model is 9.5%. Use of PrEP alone reduces this risk to 3.7%, but use of ART alone reduces the risk to 0.5%–0.6% (and provides other important health benefits of ART for the infected partner); ART plus PrEP confers minimal additional benefit (risk is reduced to 0.1%–0.2%).

Third, the authors identify key factors that influence HIV transmission and pregnancy risks. The most influential parameter is the degree to which couples limit condomless sex to peak fertility, which can be difficult to identify [19]. When couples pursue condomless sex throughout each month, the model-projected chance of the successful outcome (healthy pregnancy without HIV transmission) is lower, at 17.8%/year with no intervention, because of increased HIV transmission without improved pregnancy chance. While both interventions still provide benefit (yearly chance of successful outcome when PrEP alone is used, 23.1%; yearly chance when ART alone is used, 26.8%), adding female PrEP to male ART again adds very little (yearly chance, 27.3%). Other critical factors include the degree to which ART reduces HIV transmission, the rate of STIs and their impact on HIV transmission, and age of the female partner. The authors are developing an online tool, which they call a clinical dashboard, that will allow patients and providers to project HIV risk and pregnancy chance for individual scenarios of age, ART use, STI treatment, and timing of condomless sex.

There are challenges to implementing safer conception that are beyond the scope of this modeling analysis but are important in clinical practice. Hoffman et al. assume normal male and female fertility. Low sperm count and motility are more common in HIV-infected men, and female subfertility is higher in HIV-prevalent settings; these will reduce pregnancy chance for individual ART plus PrEP unanswered. First, to estimate the combined impact of both interventions, Hoffman et al use per-sexual-act data from separate PrEP and ART trials; this is a strength of their model-based approach in the face of limited data [3, 5]. Uncertainty about the partner’s ART use may be an important motivation for periconception PrEP. Finally, many people in serodiscordant relationships do not know the HIV status of their partners. Disclosure strategies, including couples-based HIV counseling and testing, are needed to support at-risk men and women to know whether partners are infected—an essential first step before individuals or couples can identify the need for safer conception approaches [30].

In addition to these implementation challenges, current clinical data leave several key questions about periconception PrEP unanswered. First, to estimate the combined impact of both interventions, Hoffman et al use per-sexual-act data from separate PrEP and ART trials; this is a strength of their model-based approach in the face of limited data [3, 5]. They assume an additive effect of ART and PrEP on HIV transmission risk reduction, but it

**Table 1. Strategies for Minimizing Human Immunodeficiency Virus (HIV) Transmission Risk Among HIV-Serodiscordant Couples, in Which the Male Is Infected, That Are Attempting to Conceive**

| Method                                      | Estimated Risk Reduction, % | Benefits                               | Limitations                                                                 |
|---------------------------------------------|-------------------------------|----------------------------------------|------------------------------------------------------------------------------|
| Sex without condoms limited to peak fertility | Unknown                       | Reduces cumulative HIV exposure while permitting conception | Difficult for couples to determine time of peak fertility and/or negotiate condomless sex |
| ART for the infected partner                | 96% in clinical trial [3]; approximately 64% in non-trial setting [4] | Reduces morbidity and mortality for infected partner while reducing risk of transmission to uninfected partner | Detectable HIV may remain in semen despite suppressed plasma virus Treatment refusal and sub-optimal adherence are common |
| PrEP (oral, daily FTC/TDF) for the uninfected partner [5, 6] | 63–75                      | Female controlled                     | Adherence challenges, risk of developing drug resistance if continued after HIV infection, some safety concerns regarding use during pregnancy |
| STI treatment [7, 8]                        | ≤40                          | Reduces morbidity for the treated individuals and may reduce risk of HIV acquisition and transmission | Effective as an HIV risk reduction strategy in only 2 of 4 randomized controlled trials |
| Sperm processing [9, 10]                    | Approximately 100           | Highly effective                      | Requires assisted reproductive technology (IUI, IVF, or ICSI), inaccessible to many couples |

Abbreviations: ART, antiretroviral therapy; FTC, emtricitabine; ICSI, intracytoplasmic sperm injection; IUI, intrauterine insemination; IVF, in vitro fertilization; PrEP, preexposure prophylaxis; STI, sexually transmitted infection; TDF, tenofovir disoproxil fumarate.
is biologically plausible that once transmission risks are lowered with PrEP or ART, a second intervention will have less impact than when offered alone. If so, adding PrEP to ART would confer less benefit than projected in this analysis.

Another important data gap focuses on the clinical risks of TDF when used for periconception PrEP. TDF is part of recommended ART regimens for HIV-infected pregnant women and women of childbearing age [11,12]. Toxicities among children and adults receiving TDF to treat HIV infection include loss of bone density and renal tubular dysfunction [31,32]. Although increased risks of congenital anomalies and renal disease have not been observed in >2500 infants exposed to TDF in utero as part of long-term treatment of their HIV-infected mothers, data on bone development and growth are equivocal [33–37]. Compared with TDF exposure throughout pregnancy, it is likely that risks are even lower when exposure is limited to periconception. Significant risks of miscarriage, fetal anomalies, or growth impairment were not seen in Partners PrEP participants who became pregnant and stopped PrEP at an average of 5 weeks gestation [38]. Even a small risk of toxicity, however, would reduce the rationale for using TDF-based PrEP as a back-up to ART use by the male partner if the additive risk-reduction benefit is small.

A third data gap centers around adherence to periconception PrEP. The VOICE and FEM-PrEP trials showed significant nonadherence among women, who reported trial-related barriers (ie, the use of an experimental drug and the possibility of random assignment to the placebo group), as well as pill fatigue and self-perceived low risk for HIV infection [39–42]. When used for a limited period to safely conceive, PrEP adherence could theoretically be higher, leading to greater PrEP efficacy [17].

What should patients and providers conclude from the work by Hoffman et al? Attempts at condomless sex to conceive should ideally begin by ensuring that the HIV-infected male partner is adherent to ART with a suppressed viral load, that both partners have normal fertility and are treated for STIs, and that couples identify and limit condomless sex to the time of ovulation. If these conditions are met, there is likely no benefit to adding PrEP for an HIV-uninfected female partner. In many situations, however, these criteria will not be realistic or feasible. PrEP may be a valuable tool when an HIV-infected male partner declines to receive ART, when an HIV-uninfected woman is unsure of her partner’s adherence to ART or viral suppression status, or as a so-called bridge to suppression immediately after her partner initiates ART [43].

The debate about periconception PrEP began with observational data, expert opinion, and patient demand for strategies to facilitate safer conception without assisted reproductive technology. One might think that ideal information would come from randomized trial of ART, PrEP, and ART plus PrEP, with long-term follow-up of acceptability, adherence, HIV transmission, and pregnancy outcomes. Such a trial may not be feasible, because it would require large numbers of patients and long follow-up times; even if conducted, the findings of the trial might be obsolete if newer and more-effective PrEP regimens are introduced before trial completion. As more data become available from demonstration studies of both PrEP and ART as prevention, modeling studies like the work by Hoffman et al will help patients and providers make important, individualized decisions now about the role of both ART and PrEP in safer conception.

**Notes**

**Financial support.** This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Development (grant R01HD079214) and the National Institute of Mental Health (grant K23 MH095655), National Institutes of Health; the American Society of Tropical Medicine and Hygiene/Burroughs-Wellcome fund; and the Sullivan Family Foundation.

**Potential conflicts of interest.** All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

**References**

1. Chen JL, Phillips KA, Kanouse DE, Collins RL.Miu A. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect 2001; 33:144–52, 65.

2. Case KK, Gyhs PD, Gouws E, et al. Understanding the modes of transmission model of new HIV infection and its use in prevention planning. Bull World Health Organ 2012; 90:831–8A.

3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493–505.

4. Anglemeyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2013; 4: CD009153.

5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.

6. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423–34.

7. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: Randomised controlled trial. Lancet 1995; 346:530–6.

8. Wawer MJ, Gray RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS 1998; 12:1211–25.

9. Sempri A, Levei-Setti P, Bozzo M, et al. Immunisation of HIV-negative women with processed semen of HIV-positive partners. Lancet 1992; 340:1317–9.

10. Eke AC, Oragwue C. Sperm washing to prevent HIV transmission from HIV-infected men but allowing conception in sero-discordant couples. Cochrane Database Syst Rev 2011; CD008498.

11. World Health Organization. Consolidated guidelines on the use of antiretrovirals for the treatment and prevention of HIV infection. 2013. http://www.who.int/hiv/pub/guidelines/ arv2013/download/en/index.html, Accessed 1 May 2015.

12. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Washington, DC: Department of Health and Human Services, 2014. http://aidsinfo.nih.gov/contentfiles/ byguidelines/perinatalgl.pdf, Accessed 30 April 2015.
13. Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS 2011; 25:2005–8.
14. Whetham J, Taylor S, Charlwood L, et al. Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. AIDS Care 2013; 26:332–6.
15. Boston University. NCT02233192: PrEPception: Expanding assisited reproductive pptions for serodiscordant couples. 2015. https://clinicaltrials.gov/ct2/show/NCT02233192?term=prep+boston+conception&rank=1. Accessed 1 May 2015.
16. Hunink MGM, Glazsiou PP, Siegel JE, et al. Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press, 2003.
17. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340–8.
18. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med 2013; 10:e1001511.
19. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333:1517–21.
20. Bujan L, Sergerie M, Moïnard N, et al. Decreased semen volume and spermatozoa motility in HIV-1-infected patients under antiretroviral treatment. J Androl 2007; 28:444–52.
21. Nicopoulos JD, Almeida PA, Ramsay JW, Gilling-Smith C. The effect of human immunodeficiency virus on sperm parameters and the outcome of intrauterine insemination following sperm washing. Hum Reprod 2004; 19:2289–97.
22. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: A systematic analysis of 277 health surveys. PLoS Med 2012; 9:e1001356.
23. Birkhead GS, Pulver WP, Warren BL, Hackel S, Rodríguez D, Smith L. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002–2006. Obstet Gynecol 2010; 115:1247-55.
24. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis 2015; 211:1211–8.
25. Katz IT, Essien T, Marinda ET, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 2011; 25:2177–81.
26. Aghokeng AF, Monleau M, Eymard-Duverney S, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis 2014; 58:99–109.
27. Gardner EM, McLees MP, Steiner JF, Del Rio CL. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793–800.
28. Adakum SA, Siedner MJ, Muzzoora C, et al. Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural Uganda. J Acquir Immune Defic Syndr 2013; 62:317–21.
29. Jain V, Byonanebye DM, Amanyire G, et al. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/microliter in rural Uganda. AIDS 2014; 28:2241–9.
30. World Health Organization. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: Recommendations for a public health approach. 2012. http://www.who.int/hiv/pub/guidelines/9789241501972/en/. Accessed 1 May 2015.
31. Schaefer JJ, Manlangit K, Squires KE. Bone health and human immunodeficiency virus infection. Pharmacotherapy 2013; 33:665–82.
32. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multi-ethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J 2013; 32:495–500.
33. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry: INC Research. 2015. http://www.apregistry.com/. Accessed 30 April 2015.
34. Williams PL, Crain MJ, Yildirim C, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr 2015; 169:48–55.
35. Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151–9.
36. Siberry G, Jacobson DL, Kalkwarf H, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate. In: 2014 Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 3–6 March 2014. http://www.croiwebcasts.org/console/player/22145变得更Type=slideVideo&. Accessed 1 May 2015.
37. Gibb DM, Kitzto H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:e1001217.
38. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA 2014; 312:362–71.
39. Van Damme L, Cornell A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–22.
40. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015; 372:509–18.
41. van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS One 2014; 9:e89118.
42. Cornell AL, Deese J, Wang M, et al. FEM-PrEP: Adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2014; 66:324–31.
43. Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART [abstract 24]. In: 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 23–26 February 2015. http://www.croiconference.org/sessions/near-elimination-hiv-transmission-demonstration-project-prep-and-art. Accessed 1 May 2015.